© 2021 MJH Life Sciences and Practical Cardiology. All rights reserved.
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
September 25, 2021
September 24, 2021
September 23, 2021
September 22, 2021
September 21, 2021
Coverage of ESC Congress 2021
An analysis leveraging data from NHANES, the GWTG-HF registry, and PARAGON-HF is providing insight into the potential impact of the FDA's expanded label for sacubitril/valsartan based on optimal implementation.
September 20, 2021
On September 20, Abbott announced the FDA had approved their Portico with FlexNav TAVR system for patients with symptomatic, severe aortic stenosis based on results of the PORTICO IDE Trial.
September 19, 2021
Professor Kausik Ray provides perspective on the most recent cardiovascular disease prevention guidelines debuted by the European Society of Cardiology at ESC Congress 2021.
September 17, 2021
Data from the CONNECT-HF trial from HFSA 2021 suggest use of a digital tool designed to improve adherence could contribute to improving outcomes among patients discharged from the hospital with heart failure with reduced ejection fraction.
September 16, 2021
After presenting at TMIOA's 5th Heart in Diabetes meeting, Silvio Inzucchi, MD, reviews current knowledge related to the effects of diabetes medications on stroke risk.
September 15, 2021
Presented at HFSA 2021, results of REDWOOD-HCM provide insight into the effects of the oral selective cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy.
Matthew Budoff, MD, discusses what he views as hurdles to achieving optimal prescription of newer agents in the treatment of cardiometabolic conditions, including diabetes, heart failure, dyslipidemia, and more.
September 14, 2021
Presented at HFSA 2021, PRESERVED-HF provides evidence suggesting dapagliflozin use was associated with improvements in KCCQ symptom score and 6-minute walking distance in patients with heart failure with preserved ejection fraction.
September 12, 2021
Our latest case report from Brady Pregerson, MD, features an elderly woman with a history of diabetes experiencing sweats, light-headedness, nausea, and SOB. Can you determine the correct diagnosis?
September 10, 2021
Announced in a statement on September 1, the FDA warning is an update to the FDA Drug Safety Communication issued on February 4, 2021 and the results of a review of a trial that found a serious increased risk of CV-related events with the drug.